| Drug Name |
Vernakalant hydrochloride |
| Drug ID |
BADD_D02351 |
| Description |
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. |
| Indications and Usage |
Indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for non-surgery patients that lasts for less than 7 days of duration and post-cardiac surgery patients with atrial fibrillation lasting less than 3 days of duration. |
| Marketing Status |
approved; investigational |
| ATC Code |
C01BG11 |
| DrugBank ID |
DB06217
|
| KEGG ID |
D06665
|
| MeSH ID |
C524581
|
| PubChem ID |
9930048
|
| TTD Drug ID |
D00OTL
|
| NDC Product Code |
Not Available |
| UNII |
7G4J1ZD9UQ
|
| Synonyms |
vernakalant | RSD 1235 | RSD1235 | RSD-1235 |
